IP Library Granted Patent US 11,608,344
Granted Patent B2
US 11,608,344 · App. 17/302,502 · Granted Mar 21, 2023

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Inventors: Lara C. Czabaniuk (Thousand Oaks, CA); Timothy Hopper (Thousand Oaks, CA); Jonathan B. Houze (Cambridge, MA); Jane Panteleev (Thousand Oaks, CA); Gwenaella Rescourio (Thousand Oaks, CA); Vincent Santora (Thousand Oaks, CA); Haoxuan Wang (Thousand Oaks, CA); Ryan D. White (Thousand Oaks, CA); Alice R. Wong (Thousand Oaks, CA); Yongwei Wu (Thousand Oaks, CA); Maxence Bos (Saint-Laurent, CA); John Mancuso (Saint-Laurent, CA); Ivan Franzoni (Saint-Laurent, CA)
Assignees: AMGEN INC.; VIGIL NEUROSCIENCE, INC.
C07D487/04A61P25/28C07D413/14C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,608,344
App. No.
17/302,502
Granted
Mar 21, 2023
Kind
B2
Abstract

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Claims (60)

1. A compound selected from:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

2. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

3. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

4. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

5. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

6. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

7. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

8. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

9. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

10. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

11. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

12. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

13. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

14. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

15. The compound of claim 1 , which is:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

16. A pharmaceutical composition comprising a compound selected from:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, and a pharmaceutically acceptable excipient.

17. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

18. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

19. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

20. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

21. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

22. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

23. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

24. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

25. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

26. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

27. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

28. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

29. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

30. The pharmaceutical composition of claim 16 , wherein the compound is

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2022
From: HOUZE, JONATHAN B.
To: VIGIL NEUROSCIENCE, INC.
Reel/Frame 059816/0877 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2022
From: BOS, MAXENCE; MANCUSO, JOHN; FRANZONI, IVAN
To: NUCHEM THERAPEUTICS INC.
Reel/Frame 059817/0193 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2022
From: NUCHEM THERAPEUTICS INC.
To: VIGIL NEUROSCIENCE, INC.
Reel/Frame 059817/0240 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2022
From: CZABANIUK, LARA C.; HOPPER, TIMOTHY; PANTELEEV, JANE; RESCOURIO, GWENAELLA; SANTORA, VINCENT; WANG, HAOXUAN; WHITE, RYAN D.; WONG, ALICE R.; WU, YONGWEI
To: AMGEN INC.
Reel/Frame 059855/0446 →
Continuity (2)
Provisional Application 63019772 · May 4, 2020
Related Publication 20230002390A1 · Jan 5, 2023
Cited By (3)
US 12,252,489 US 12,319,691 US 12,428,425